In addition, certain selling stockholders have granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock at the public offering price, less underwriting discounts and commissions. A preliminary prospectus supplement relating to and describing the terms of the offering was filed with the SEC and is available on the SEC’s website at www.sec.gov. Gross proceeds to BTI from the offering are expected to be $200 million, before deducting underwriting discounts and commissions and offering expenses. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. {data.pricedata.lasttradedatetime | momentjs 'true' 'LLL' tLang} {data.tz | asTimezone tLang}BXCL701 is an investigational orally-available systemic innate immunity activator in development for the treatment of a rare form of prostate cancer and for the treatment of pancreatic cancer.Our neuroscience and immuno-oncology programs utilize our approach to drug development.BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company that utilizes novel artificial intelligence, or AI, to identify the next wave of medicines across neuroscience and immuno-oncology. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. Any such forward-looking statements represent management’s estimates as of the date of this press release. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. All forward-looking statements are based upon BTI's current expectations and various assumptions. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; impacts from the COVID-19 pandemic; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2020 as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov.
These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release.Contact Information Investor Relations: John Graziano [email protected] 1.646.378.2942Media: Julia Deutsch [email protected] 1.646.378.2967Subscribe to Premium to view Fair Value for BTAI BioXcel Therapeutics, Inc. (“BTI” or “Company”) (BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (“USPTO”) for patent application No.
Parole In Place Denied, Caboolture News Contact, Full List Of Costco Locations, Inside Out Definition, Where Is Bareminerals Manufactured, Park Tool Prs-23, Marcelo Saracchi Sofifa, Kent County Obits,